<DOC>
	<DOC>NCT00681317</DOC>
	<brief_summary>This is a study to evaluate safety, tolerability, PK and PD effects of orally administered AZD6280 after single and repeated ascending doses.</brief_summary>
	<brief_title>AZD6280 Multiple Ascending Dose Study</brief_title>
	<detailed_description />
	<criteria>Female subjects must be of nonchild bearing potential. Clinically significant illness within 2 weeks before the study start. Enrollment in another concurrent investigational study or intake of an investigational drug within 30 days or intake of an investigational drug within a period of 5 half lives of that drug prior to the screening visit Blood loss in excess of 200 mL within 30 days of Day 2, in excess of 400 mL within 90 days of Day 2, or in excess of 1200 mL within 1 year of Day 2 Clinically relevant abnormalities in physical examinations, vital signs, ECG, clinical chemistry, hematology or urinalysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>